Overview

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
Phase:
Phase 2
Details
Lead Sponsor:
University of California, Davis
Collaborators:
Doris Duke Charitable Foundation
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Alendronate